bioAffinity Technologies (BIAF) Total Current Liabilities (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Total Current Liabilities for 6 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 6.75% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 6.75% YoY), while the FY2025 annual figure was $2.9 million, down 6.4% from the prior year.
• Total Current Liabilities improved to $3.2 million in Q1 2026 per BIAF's latest filing, from $2.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $3.4 million in Q1 2025 and bottomed at $775151.0 in Q2 2023.
• Historically, Total Current Liabilities has averaged $2.2 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 91.27% — and 2024, when it soared 200.11%.
• bioAffinity Technologies' Total Current Liabilities stood at $1.1 million in 2022, then soared by 97.41% to $2.2 million in 2023, then jumped by 38.13% to $3.1 million in 2024, then dropped by 6.4% to $2.9 million in 2025, then advanced by 9.59% to $3.2 million in 2026.
• Business Quant data shows BIAF's Total Current Liabilities at $3.2 million in Q1 2026, $2.9 million in Q4 2025, and $2.4 million in Q3 2025.